LAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Standard BioTools's current ratio for the quarter that ended in Dec. 2024 was 5.70.
Standard BioTools has a current ratio of 5.70. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Standard BioTools's Current Ratio or its related term are showing as below:
During the past 13 years, Standard BioTools's highest Current Ratio was 5.70. The lowest was 1.45. And the median was 3.11.
The historical data trend for Standard BioTools's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Current Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
2.17 | 1.45 | 4.81 | 1.45 | 5.70 |
Standard BioTools Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Current Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.45 | 4.50 | 3.88 | 3.76 | 5.70 |
For the Medical Devices subindustry, Standard BioTools's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Current Ratio distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Standard BioTools's Current Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Current Ratio (A: Dec. 2024 ) | = | Total Current Assets (A: Dec. 2024 ) | / | Total Current Liabilities (A: Dec. 2024 ) |
= | 375.88 | / | 65.894 | |
= | 5.70 |
Standard BioTools's Current Ratio for the quarter that ended in Dec. 2024 is calculated as
Current Ratio (Q: Dec. 2024 ) | = | Total Current Assets (Q: Dec. 2024 ) | / | Total Current Liabilities (Q: Dec. 2024 ) |
= | 375.88 | / | 65.894 | |
= | 5.70 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (NAS:LAB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Standard BioTools's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Casdin Partners Master Fund, L.p. | director, 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Martin D Madaus | director | 290 CONCORD ROAD, BILLERICA MA 01821 |
Jeffrey G. Black | officer: SVP & Chief Financial Officer | 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Eli Casdin | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Partners Fo1-msv, Lp | director | C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Private Growth Equity Fund Ii Gp, Llc | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Partners Gp, Llc | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Capital, Llc | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Private Growth Equity Fund Ii, L.p. | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Fenel M Eloi | director | C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Frank Witney | director | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Jeremy Steven Davis | officer: SVP Chief Commercial Officer | C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080 |
Hanjoon Alex Kim | officer: Chief Operating Officer | C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080 |
Michael Egholm | director, officer: President & CEO | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
From GuruFocus
By Marketwired • 09-18-2024
By Marketwired • 05-28-2024
By GuruFocus News • 10-31-2024
By GuruFocus News • 10-31-2024
By Marketwired • 01-13-2025
By GuruFocus News • 03-05-2025
By GuruFocus News • 11-15-2024
By Marketwired • 07-31-2024
By Marketwired • 02-12-2025
By Marketwired • 01-08-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.